InsiderClue
← All stocks

Kyverna Therapeutics, Inc.

KYTX Net buying
CIK 0001994702 #3077 in the set updated 19 Sep 2026
Bought (120 mo)
$47.39M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$292.78K
$0.00 on a plan · $292.78K straight out of an exercise
Sold at will
$0.00
0 of 1 sales
Net
+$47.10M
+$47.39M against sales at will

By person

19 insiders · 11 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
GILEAD SCIENCES, INC. entity
10% owner
$20.02M (1)
—
+$20.02M
4,126,119
6.67%
$30.95M
—
Bain Capital Life Sciences Investors, LLC entity
10% owner
$9.90M (1)
—
+$9.90M
3,163,868
5.12%
$23.73M
—
Northpond Ventures III GP, LLC entity
Former 10% Owner
$9.90M (1)
—
+$9.90M
450,000
0.7276%
$3.38M
—
Vida Ventures, LLC entity
10% owner
$5.57M (2)
—
+$5.57M
583
0.0009%
$4.37K
—
SEIDENBERG BETH C
Director
$1,000.00K (1)
—
+$1,000.00K
891,044
1.44%
$6.68M
—
Westlake BioPartners Opportunity Fund I, L.P. entity
10% owner
$1,000.00K (1)
—
+$1,000.00K
869,317
1.41%
$6.52M
+18.1%
Walker Karen Marie
Chief Technology Officer
—
$292.78K (1) scheduled
−$292.78K
22,636
0.0366%
$169.77K
—
Cohen Fred E
Director
—
—
—
4,545,651
7.35%
$34.09M
—
Westlake BioPartners Fund I, L.P. entity
10% owner
—
—
—
735,984
1.19%
$5.52M
—
Shaw Christi
Executive Chairperson
—
—
—
66,741
0.1079%
$500.56K
—
Biddle Warner Weston
Chief Executive Officer
—
—
—
58,000
0.0938%
$435.00K
—
Jones Ryan Alexander
Chief Financial Officer
—
—
—
55,950
0.0905%
$419.63K
+115.7%
CLARK IAN T
Director
—
—
—
21,727
0.0351%
$162.95K
—
Aktar Mert
Director
—
—
—
21,727
0.0351%
$162.95K
—
GEHCHAN NAJI
See Remarks
—
—
—
18,000
0.0291%
$135.00K
—
SPIEGELMAN DANIEL K
Director
—
—
—
16,634
0.0269%
$124.76K
—
Emany Sravan Kumar
Director
—
—
—
11,006
0.0178%
$82.55K
—
Miller Andrew Craig
Director
—
—
—
11,006
0.0178%
$82.55K
—
GRASSO MARC
Chief Financial Officer
—
—
—
10,000
0.0162%
$75.00K
—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 41
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 5
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 1
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 27,194,442
History held since 12 Feb 2024